TerminatedInterventionalEarly Phase 1Updated Mar 10, 2017
Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy | NCT02173132 | Trialant
CompletedInterventionalPhase 3Updated Jun 24, 2014
Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy
ClinicalTrials.gov ID
NCT02173132
Lead Sponsor
University of CataniaOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
94Actual
Last Update Posted
Jun 24, 2014Estimated
Start Date
Apr 2010
Primary Completion Date
Nov 2013Actual
Brief Summary
This study evaluated the effects of acetyl-L-carnitine treatment on Perceived Work Stress, Work Ability and Work Performance in subjects with Hepatic Encephalopathy.
Work Stress
Work Ability
Work Performance
Acetyl-L-carnitine
Placebo
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
overt hepatic encephalopathy (HE) or a history of overt HE
Exclusion Criteria:
history of recent alcohol intake; infection; recent antibiotic use or gastrointestinal bleeding; history of recent use of drugs affecting psychometric performances like benzodiazepines, antiepileptics or psychotropic drugs; a history of shunt surgery or transjugular intrahepatic portosystemic shunt for portal hypertension; electrolyte imbalance; renal impairment; hepatocellular carcinoma; severe medical problems such as congestive heart failure, pulmonary disease or neurological or psychiatric disorder that could influence quality of life measurement; inability to perform neuropsycological tests.